The combination of AXL inhibitor ONO-7475 and venetoclax demonstrated significant synergistic effects in FLT3-ITD+ MV4-11 and MOLM-13 AML cell lines, enhancing apoptosis and reducing cell viability compared to single agent therapy [113]. Here, AXL is linked to acute myeloid leukemia.